What is the main purpose of this 8-K filing?

The main purpose of this 8-K filing is to disclose sworn statements from Pfizer's Principal Executive Officer and Principal Financial Officer, addressing matters related to the company's compliance with Exchange Act filings. It's a disclosure focused on corporate governance and regulatory adherence, rather than financial performance.

Does this filing provide any new financial information or business updates for Pfizer?

No, this specific 8-K filing does not contain any new financial results, earnings updates, or operational business developments. It is solely focused on attaching sworn statements from company officers regarding their compliance with Exchange Act reporting requirements.

What are the 'Exchange Act Filings' mentioned in the report?

Exchange Act Filings refer to reports and documents that public companies, like Pfizer, are required to file with the U.S. Securities and Exchange Commission (SEC) under the Securities Exchange Act of 1934. These filings include annual reports (10-K), quarterly reports (10-Q), and current reports (8-K), among others, which provide information to investors about the company's financial condition and operations.

Why would Pfizer need to file sworn statements from its officers about Exchange Act Filings?

Filing sworn statements from top officers often indicates a heightened level of scrutiny or a specific need to formally attest to the accuracy and completeness of previous or ongoing regulatory filings. This could be in response to internal reviews, regulatory inquiries, or to bolster investor confidence in the company's reporting integrity during a particular period.

PFE 8-K SEC Disclosure — Aug 13, 2002

Summary

Pfizer Inc. (PFE) filed an 8-K report on August 13, 2002, primarily to disclose sworn statements from its Principal Executive Officer and Principal Financial Officer. These statements, attached as Exhibits 99.1 and 99.2, address "facts and circumstances relating to Exchange Act Filings." While the specific details within these sworn statements are not elaborated upon in the provided 8-K summary, their inclusion suggests a need for transparency and attestation regarding the company's adherence to securities laws and reporting obligations at that time. Investors should note that this filing does not contain new financial results or operational updates, but rather focuses on corporate governance and compliance matters.

Key Highlights

1Pfizer Inc. filed an 8-K report on August 13, 2002.
2The filing's primary purpose is to disclose sworn statements from key executives.
3Exhibits 99.1 and 99.2 contain Statements Under Oath from the Principal Executive Officer and Principal Financial Officer.
4These statements concern "facts and circumstances relating to Exchange Act Filings."
5The report does not include new financial results or operational performance data.
6This filing emphasizes corporate governance and compliance with securities regulations.

PFIZER INC 8-K Report (Aug 13, 2002)

Summary

Key Highlights

Frequently Asked Questions